Insulin lispro protamine(25R) (Lilly )

精蛋白锌重组赖脯胰岛素(25R)(礼来)

Report date: 2023/11/15 10:40:31

Base Information

Drug NameInsulin lispro protamine(25R) (Lilly )
Drug Alias Name精蛋白锌重组赖脯胰岛素混合注射液（25R）
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLilly Suzhou Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLilly Suzhou Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A